Repair Biotechnologies’ REP-0004 mRNA therapy gains FDA orphan drug designation and demonstrates rapid plaque regression in mouse models, potentially revolutionizing cardiovascular care. An mRNA...
First-in-human trial shows Cyclarity’s UDP-003 can safely bind and excrete 7-ketocholesterol, potentially reversing atherosclerosis. Cyclarity Therapeutics’ UDP-003 achieves first safe removal...
